このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

上後鋸筋肋間筋面ブロック対硬膜内モルヒネ:VATS手術における比較

2026年10月1日 更新者:Cengiz KAYA、Ondokuz Mayıs University

ビデオ補助胸腔鏡手術を受ける患者における術後急性疼痛に対する後上鋸筋肋間平面ブロックと髄腔内モルヒネの効果の比較

This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.

The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.

The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.

Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.

The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.

Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.

This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.

研究の種類

介入

入学 (実際)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age between 18 and 75 years
  • American Society of Anesthesiologists physical status I to III
  • Scheduled for elective video-assisted thoracoscopic surgery, including wedge resection, segmentectomy, or lobectomy

Exclusion Criteria:

  • Refusal to participate
  • Pregnancy
  • Morbid obesity (body mass index greater than 40 kg per square meter)
  • Allergy to study medications
  • Neuropsychiatric disorders, cognitive impairment, or inability to communicate
  • History of substance abuse
  • Active systemic infection or infection at the planned injection site
  • Severe cardiac, respiratory, hepatic, renal, or endocrine disease.
  • Chronic pain syndrome or ongoing chronic pain treatment
  • Emergency surgery or previous ipsilateral VATS or thoracotomy
  • Preoperative opioid use: ≥15 mg oral morphine equivalents/day for ≥30 days within the previous 3 months.
  • Anticipated need for postoperative mechanical ventilation.
  • Contraindications to neuraxial or peripheral regional anesthesia, including anticoagulant therapy, coagulopathy, infection, or relevant anatomical abnormalities.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intrathecal Morphine

Participants receive intrathecal morphine before induction of general anesthesia. Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.

Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally before induction of general anesthesia.

実験的:Serratus Posterior Superior Intercostal Plane Block

Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.

Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Cumulative IV-MME during the first 24 hours after postoperative admission following extubation
時間枠:24 hours

Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia.

24 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Cumulative IV-MME during the first 12 hours after postoperative admission following extubation
時間枠:12 hours

Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents

12 hours
Postoperative pain scores
時間枠:0, 3, 6, 12, 18, and 24 hours postoperatively

Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity.

0, 3, 6, 12, 18, and 24 hours postoperatively
Time to first patient-controlled analgesia demand
時間枠:24 hours

Time from postoperative admission to the first PCA morphine demand.

24 hours
Quality of recovery score
時間枠:Preoperative baseline, 24 hours postoperatively, and at discharge

Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery.

Preoperative baseline, 24 hours postoperatively, and at discharge
Postoperative nausea and vomiting
時間枠:0, 3, 6, 12, 18, and 24 hours postoperatively

Postoperative nausea and vomiting (PONV) will be assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Scores >1 will be treated with ondansetron 4 mg IV; persistent symptoms will be treated with intravenous metoclopramide.

0, 3, 6, 12, 18, and 24 hours postoperatively
Sedation level
時間枠:0, 3, 6, 12, 18, and 24 hours postoperatively

Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli.

0, 3, 6, 12, 18, and 24 hours postoperatively
Respiratory depression
時間枠:24 hours

Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute

24 hours
Pruritus
時間枠:0, 3, 6, 12, 18, and 24 hours postoperatively

Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms.

0, 3, 6, 12, 18, and 24 hours postoperatively
Block-related complications
時間枠:Up to 30 days postoperatively

Incidence of post-dural puncture headache, paresthesia, hematoma, and local anesthetic systemic toxicity associated with the study interventions.

Up to 30 days postoperatively
Postoperative complications
時間枠:30 days

Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications.

30 days
Remifentanil consumption
時間枠:Intraoperative period (from induction to end of surgery), up to 4 hours

Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg).

Intraoperative period (from induction to end of surgery), up to 4 hours
Rescue analgesia requirement
時間枠:24 hours

Incidence of patients requiring additional analgesia beyond patient-controlled analgesia

24 hours
Incidence of postoperative nausea and/or vomiting
時間枠:24 hours postoperatively

Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV.

24 hours postoperatively
Propofol consumption
時間枠:Intraoperative period (from induction to end of surgery), up to 4 hours

Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg).

Intraoperative period (from induction to end of surgery), up to 4 hours
Area under the numeric rating scale-time curve
時間枠:0 to 24 hours postoperatively

The area under the numeric rating scale-time curve from 0 to 24 postoperative hours will be calculated separately for pain at rest and during activity using pain scores measured at 0, 3, 6, 12, 18, and 24 hours and the trapezoidal rule. Higher values indicate a greater cumulative pain burden.

0 to 24 hours postoperatively
Comprehensive Complication Index
時間枠:Up to 30 days postoperatively

Overall postoperative morbidity will be quantified using the Comprehensive Complication Index, which integrates all postoperative complications graded according to the Clavien-Dindo classification into a continuous score ranging from 0 to 100. Higher scores indicate greater overall morbidity.

Up to 30 days postoperatively

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月15日

一次修了 (実際)

2026年8月15日

研究の完了 (実際)

2026年9月15日

試験登録日

最初に提出

2026年4月9日

QC基準を満たした最初の提出物

2026年4月16日

最初の投稿 (実際)

2026年4月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月1日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SPSIPITM1

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。